Targeted Oncology Expands in FGFR2 and EGFR Exon 20 Cancers

Lirafugratinib is FDA-approved for previously treated FGFR2-rearranged intrahepatic cholangiocarcinoma, with approximately 46% response and 11.8-month median response duration in phase 2 single-arm data. Zipalertinib plus platinum chemotherapy improved PFS in first-line EGFR exon 20 insertion NSCLC and is moving toward FDA review, but detailed efficacy, safety, and regulatory decisions remain pending.